Abstract 488P
Background
Clinical investigations have great interest in understanding how ground-glass opacities (GGO) evolve into solid nodular lung adenocarcinoma (LUAD). However, there exists a dearth of research on ecosystem-level dynamics. Comprehensive insights into this phenomenon hinge on patient biopsies, which, when coupled with advanced single cell studies, hold the potential to unravel the intricacies of GGO progression and its transition into solid nodular LUAD.
Methods
We implemented a machine-learning framework to analyze scRNA-seq and WGS data derived from 55 patients stratified based on radiological patterns. In combination with in situ multiplex IF and HLA-immunopeptidome, we analysed the immune-ecosystem associated neoantigen presentation, followed by validation with HLA-tetramer CD8 T cell assay. Based on these methods, we consequently refined early-stage LUAD classification.
Results
We defined six lung immune multicellular ecotypes (LIMEs), in which two cancer cell state-associated LIMEs were implicated in distinct radiological patterns. These early stage malignant cells, through presenting GGO-associated neoantigens, were recognized by CXCL13+ CD8 T cells that formed an anti-tumoral LIME with other stromal cells. Solid nodular specific LIMEs, containing CTHRC1+ CAFs, SPP1+ TAMs and BANK1+ B cells, through inter-ecotype interactions, drove CD8 T cell exhaustion, leading to tumour progression.
Conclusions
This work offers an ecosystem-level portrayal of early-stage LUAD. It furnishes a resource for delving into the pre-malignant transformation of lung epithelium and its associated microenvironment. It outlines both intrinsic and extrinsic mechanisms that underpin the emergence of GGO and subsolid patterns. It imparts biological rationales as to select patients with early-stage LUAD might benefit from perioperative adjuvant therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
West China Hospital, Sichuan University, Chengdu, China.
Funding
National Science Fondation of China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract